Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 10/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.42 |
| ▸ | PDE1A | P54750 | 7/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4952368 | 1.00 | PDE1B (0.42) | PDE1BPDE1CPDE1AADORA3ADORA2A | |
| SCHEMBL4951394 | 0.93 | LRRK2 (0.39) | PDE1BPDE1CPDE1ALRRK2 | |
| SCHEMBL4931029 | 0.85 | ADORA2A (0.39) | ADORA2AADORA2B | |
| SCHEMBL4937428 | 0.82 | ROCK2 (0.42) | ADORA2AADORA2BBRD4 | |
| SCHEMBL4951461 | 0.81 | LRRK2 (0.44) | PDE1BBRD4LRRK2 | |
| SCHEMBL4935601 | 0.80 | ROCK2 (0.41) | BRD4MKNK1MKNK2 | |
| SCHEMBL4935343 | 0.80 | ROCK2 (0.41) | BRD4MKNK1MKNK2 | |
| SCHEMBL4951836 | 0.80 | GRM1 (0.33) | — | |
| SCHEMBL4933819 | 0.78 | POLB (0.41) | LRRK2 | |
| SCHEMBL4951407 | 0.78 | MAPT (0.44) | BRD4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | PDE5A, PDE3B, PDE4A | PDE1B 210/4885PDE1C 203/4885PDE1A 172/4885 |
| US-20060089375-A1 | Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE5A, PDE3B, PDE4A | PDE1B 210/4885PDE1C 203/4885PDE1A 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.